Abstract: Proposed is an all-solid-state battery including a self-standing sheet layer positioned on a negative electrode current collector. The all-solid-state battery may include the negative electrode current collector, the self-standing sheet layer positioned on the negative electrode current collector, a solid electrolyte layer positioned on the sheet layer, a positive electrode active material layer positioned on the solid electrolyte layer, and a positive electrode current collector positioned on the positive electrode active material layer. The sheet layer contains carbon nanotubes.

Abstract: An emissive display device includes a display area which includes a plurality of pixels, and a driver disposed at a side of the display area, where the driver includes at least two emission signal stages disposed in one row, and an input signal line connected to the emission signal stages, and the at least two emission signal stages are connected to the same input signal line.

Abstract: The present invention relates to a use of a recombinant protein in which an interferon-beta protein and an antibody binding to a HER2 antigen are fused for the purpose of treating cancer patients of which the HER2 expression level is IHC 1+ or higher. The recombinant protein can exhibit efficacy better than conventional antibody therapeutic agents through cancer-specific anti-cancer immune responses in patients, thereby being used for more patients, and thus is effectively usable as a novel agent for treating cancer.

Abstract: The present invention relates to a method for predicting the prognosis of breast cancer patients by using gene deletions and, more particularly, to: a method for detecting a marker for the prognosis of triple negative breast cancer patients in order to provide information necessary for the breast cancer prognosis diagnosis, comprising the steps of obtaining a sample of a subject, extracting genomic DNA from the sample, examining deletions of genes in the extracted genomic DNA, and determining that a subject, in which gene deletions in genomic DNA are confirmed, has a poor prognosis for breast cancer; and a composition for predicting the prognosis of breast cancer patients, containing a preparation enabling the examination of gene deletions and a kit comprising the same as an active ingredient.